Utilidad de los fármacos antiobesidad en la diabetes mellitus tipo 2

Lobstein, 2004, The prevention of obesity in children, Pediatr Endocrinol Rev., 1, 471 Flegal, 2002, Prevalence and trends in obesity among US adults, 1999–2000, JAMA., 288, 1723, 10.1001/jama.288.14.1723 Jung, 1997, Obesity as a disease, Br Med Bull., 53, 307, 10.1093/oxfordjournals.bmb.a011615 Iniciativa NAOS. Available on: http://www.naos.aesan.msps.es. Torgerson, 2004, XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients, Diabetes Care., 27, 155, 10.2337/diacare.27.1.155 Chanoine, 2005, Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial, JAMA., 293, 2873, 10.1001/jama.293.23.2873 European Medicines Agency. Press release 21 January 2010. Available on: www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf Caterson, 2010, Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT Lead-in Period, Obesity (Silver Spring)., 18, 987, 10.1038/oby.2009.327 James, 2000, Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance, Lancet, 356, 2119, 10.1016/S0140-6736(00)03491-7 Arterburn, 2004, The efficacy and safety of sibutramine for weight loss: a systematic review, Arch Intern Med., 164, 994, 10.1001/archinte.164.9.994 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm. Ong, 2006, Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes, Diabetes Care., 29, 2361, 10.2337/dc06-0827 Bryson, 2009, Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers, Br J Clin Pharmacol., 67, 309, 10.1111/j.1365-2125.2008.03311.x Thomsen, 2008, Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization, J Pharmacol Exp Ther., 325, 577, 10.1124/jpet.107.133348 Salem, 2010, Approaches to the pharmacological treatment of obesity, Expert Rev Clin Pharmacol., 3, 73, 10.1586/ecp.09.54 Vivus Pharmaceuticals, 2009 Bray, 2003, A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity, Obes Res., 11, 722, 10.1038/oby.2003.102 Orexigen Therapeutics. Orexigen® Therapeutics presents additional NB-302 Contrave® data at American Diabetes Association (ADA). 69th Scientific Sessions. Available on: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irolnewsArticle&ID=1296807&highlight Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7–36)amide on ad libitum energy intake in humans, J Clin Endocrinol Metab., 86, 4382, 10.1210/jc.86.9.4382 Naslund, 2004, Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects, Br J Nutr., 91, 439, 10.1079/BJN20031064 Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology., 136, 3585, 10.1210/en.136.8.3585 Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis, JAMA., 298, 194, 10.1001/jama.298.2.194 Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and bodyweight in subjects with type 2 diabetes, Diabetes Care., 30, 1487, 10.2337/dc06-2375 Barnett, 2007, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial, Clin Ther., 29, 2333, 10.1016/j.clinthera.2007.11.006 Blonde, 2009, The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies, Diabetes Obes Metab., 11, 26, 10.1111/j.1463-1326.2009.01075.x Buse, 2009, LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet., 374, 39, 10.1016/S0140-6736(09)60659-0 Aronne, 2007, Progressive reduction in bodyweight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study, J Clin Endocrinol Metab., 92, 2977, 10.1210/jc.2006-2003 Trevaskis, 2010, Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats, Obesity (Silver Spring)., 18, 21, 10.1038/oby.2009.187 Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy, Obesity (Silver Spring)., 17, 1736, 10.1038/oby.2009.184 Buchwald, 2005, Consensus Conference Panel. Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers, J Am Coll Surg, 200, 593, 10.1016/j.jamcollsurg.2004.10.039 Schauer, 2003, Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus, Ann Surg., 238, 467, 10.1097/01.sla.0000089851.41115.1b